Press Releases

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -

- Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms -

- Positive Interim Results are Highly Consistent with Results from the Phase 3 RESPONSE Study of Seladelpar -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD),... (continue reading...)

Results from a Phase 2 study show combination of OCA 5-10mg and bezafibrate 400mg induced the greatest percent change from baseline in ALP at Month 6

OCA and bezafibrate combination therapy has acceptable metabolic profile

Results featured in podium presentation today at DDW 2024

MORRISTOWN, N.J., May 18, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused... (continue reading...)

London, England, May 18, 2024 (GLOBE NEWSWIRE) --

At a recent financial technology conference, the CEO of ValueZone, Adam Carl Waldman, committed to positioning ValueZone as a frontrunner in cutting-edge quantitative trading platforms, designed specifically to boost passive income for its users. This strategic pivot aims to harness sophisticated quantitative algorithms to maximize returns and minimize risks, marking a significant step in the evolution of... (continue reading...)

London, England, May 18, 2024 (GLOBE NEWSWIRE) --

StakingFarm, a pioneering force in the cryptocurrency staking sector, proudly announces its role in facilitating substantial wealth generation for its users through its robust crypto-staking platform. By capitalizing on the burgeoning field of cryptocurrency, StakingFarm provides a secure and efficient means for individuals to earn passive income and thereby increase their financial well-being.

"Staking has... (continue reading...)

– Two poster presentations of Mallinckrodt's research for adults with HRS with rapid reduction in kidney function1 provide further insight into treatment with TERLIVAZ for appropriate patients –

DUBLIN, May 18, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney... (continue reading...)